A Chinese patient with Rothmund–Thomson syndrome

Juan Zeng[1](#page-0-0) | **Jiayi L[i2,3](#page-0-1)** | **Yuwei Li[u2,3](#page-0-1)** | **Rui Liang[2](#page-0-1)** | **Lin Wang[2](#page-0-1)** | **Qing Zhou[2](#page-0-1)** | **Jinghua Sun[2](#page-0-1)** | **Zhongzhen Li[u2](#page-0-1)** | **Wen-Jing Wang[2](#page-0-1)** | **Sujun Zhu[1](#page-0-0)**

1 Obstetrics Department, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong Province, China

2 BGI-Shenzhen, Shenzhen, China

3 College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China

Correspondence

Wen-Jing Wang, BGI-Shenzhen, Shenzhen 518083, China. Email: wangwenjing@genomics.cn

Sujun Zhu, Obstetrics Department, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong Province 518028, China. Email: zhusj1223@126.com

Funding information

Science Technology and Innovation Commission of Shenzhen Municipality, Grant/Award Number: JCYJ20170412152854656

Abstract

Introduction: Rothmund–Thomson syndrome (RTS) is a rare autosomal recessive disorder that has been reported in all ethnicities, with several identifiable pathogenic variants. There have been reported cases indicating that RTS may lead to low birth weight in fetuses, but specific data on the fetal period are lacking. Genetic testing for RTS II is currently carried out by identifying pathogenic variants in *RECQL4*.

Methods: In order to determine the cause, we performed whole-genome sequencing (WGS) analysis on the patient and his parents. Variants detected by WGS were confirmed by Sanger sequencing and examined in family members.

Results: After analyzing the WGS data, we found a heterozygous nonsense mutation c.2752G>T (p.Glu918Ter) and a novel frameshift insertion mutation c.1547dupC (p.Leu517AlafsTer23) of *RECQL4*, which is a known pathogenic/ disease-causing variant of RTS. Further validation indicated these were compound heterozygous mutations from parents.

Conclusion: Our study expands the mutational spectrum of the *RECQL4* gene and enriches the phenotype spectrum of Chinese RTS patients. Our information can assist the patient's parents in making informed decisions regarding their future pregnancies. This case offers a new perspective for clinicians to consider whether to perform prenatal diagnosis.

KEYWORDS

pathogenic compound heterozygous mutations, prenatal diagnosis, *RECQL4*, Rothmund– Thomson syndrome

1 | **INTRODUCTION**

Rothmund–Thomson syndrome (RTS; OMIM #268400) is a rare autosomal recessive disorder with a diagnostic hallmark of a facial rash in infancy, growth delay leading to short stature, and, in some cases, intrauterine growth

restriction during pregnancy (although there are no specific data on the fetal period) (Larizza et al., [2013](#page-7-0)). Other clinical features include thinning hair, sparse or absent eyelashes and eyebrows, juvenile cataracts, and susceptibility to osteosarcoma (Kitao et al., [1999](#page-6-0)). The worldwide incidence of RTS II is less than 1/1,000,000 (Aymé, [2023\)](#page-6-1),

Juan Zeng and Jiayi Li should be regarded as joint first authors.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2023 The Authors. *Molecular Genetics & Genomic Medicine* published by Wiley Periodicals LLC.

2 of 8 **WII FY** Molecular Genetics & Genomic Medicine

and more than 400 cases have been reported in the literature to date (Larizza et al., [2010;](#page-7-1) Larizza et al., [2013\)](#page-7-0). The current method for genetic testing for RTS involves identifying biallelic pathogenic variants in *ANAPC1* (RTS I) or *RECQL4* (RTS II) through molecular genetic testing (Ajeawung et al., [2019;](#page-6-2) Wang et al., [2003](#page-7-2)). The *RECQL4* gene is located in a small 6.5kb genomic region on human chromosome 8q24.3 and belongs to the DNA helicase RecQ gene family. It spans 21 exons and contains many small introns of less than 100bp (Kitao et al., [1999\)](#page-6-0). Therefore, mutations in both introns and exons of *RECQL4* can lead to Rothmund–Thomson syndrome (RTS) (Wang et al., [2002](#page-7-3)). *RECQL4* mutations are typically predicted to result in premature stop codons, missense mutations, or frameshifts that are expected to truncate the protein before the helicase domain (encoded by exons 8-14) (Siitonen et al., [2009](#page-7-4)) or disrupt the reading frame within (Siitonen et al., [2009\)](#page-7-4). Over 100 clinically relevant mutations have been identified in the *RECQL4* gene (Siitonen et al., [2009\)](#page-7-4). The *RECQL4* gene encodes a protein of 1208 amino acids in length, called the RECQL4 protein, and this protein contains a conserved core RecQ helicase domain (Kitao et al., [1998](#page-6-3); Liu, [2010](#page-7-5)). The activity of this helicase is associated with various cellular processes, including the initiation of DNA replication, DNA damage repair, base and nucleotide excision repair, homologous recombination, chromosomal telomere maintenance, mitochondrial biogenesis, and genomic stability (Ghosh et al., [2012](#page-6-4); Kim et al., [2021](#page-6-5); Lu & Davis, [2021](#page-7-6); Sangrithi et al., [2005](#page-7-7); Xu & Liu, [2009\)](#page-7-8).

2 | **MATERIALS AND METHODS**

2.1 | **Ethics declaration**

This study was approved and guided by the Shenzhen Maternity and Child Healthcare Hospital [project: SFYLS (2019)-137] and was conducted in accordance with the criteria of the Declaration of Helsinki. Informed consent was obtained from the patient's parents.

2.2 | **Patient information**

The patient of the study is a 3-month-old Chinese male infant with red rashes on his face, sparse hair, no eyelashes, and no eyebrows. We collected the umbilical cord blood and placenta of the patient and the peripheral blood of his parents from our cohort study on pregnancy. We also collected and sorted out the pregnancy examinations of the child's mother and follow-up data of the patient from the Shenzhen Maternity and Child Healthcare Hospital.

2.3 | **Whole-genome sequencing (WGS)**

To determine the cause of these symptoms, we collected the patient's umbilical cord blood and placenta, along with peripheral blood from his parents in the prenatal cohort study of our research group. Wholegenome sequencing (WGS) analysis was performed on all samples. The umbilical cord blood, placenta, and peripheral blood were stored at −20°C for a maximum of 3 days. Genomic DNA from the blood cells was extracted using the DNeasy Blood & Tissue Kit. The DNA concentration was measured using the Qubit Fluorometer 3.0, and WGS libraries were constructed using the BGISEQ-500 Library Kit. Each sample's library was sequenced on the DNBSEQ-T1 platform, generating at least 600 million reads in 2×100 pairedend reads (~40× coverage from ~120 Gb raw data for each sample) (Kang et al., [2022\)](#page-6-6).

2.4 | **Variant analysis**

After the adapter trimming and filtering of the reads, Burrows–Wheeler Alignment Tool (BWA) was used to align the clean reads to the hg19 human genome reference. The Genome Analysis Toolkit (GATK) was utilized for the detection of single-nucleotide variants (SNVs) and insertion–deletions (Indels) (Ren et al., [2018\)](#page-7-9). Copy number variants (CNVs) were detected using PSCC software (Li et al., [2014\)](#page-7-10). Public population databases, including the Single Nucleotide Polymorphism Database (dbSNP) (Sherry et al., [2001\)](#page-7-11), 1000 Genomes (phase III) (Fairley et al., [2019](#page-6-7)), NHLBI Exome Sequencing Project (ESP) (Exome Variant Server, [2022\)](#page-6-8), and the Genome Aggregation Database (gnomAD) (Karczewski et al., [2020](#page-6-9)), were used for reference. All variants in the coding region were subjected to in silico prediction tools for mutation pathogenicity, such as Scale-Invariant Feature Transform (SIFT) (Kumar et al., [2009](#page-6-10)), Polymorphism Phenotyping v2 (PolyPhen2) (Adzhubei et al., [2010](#page-6-11)), likelihood-ratio test (LRT), and MutationTaster (Schwarz et al., [2014](#page-7-12)).

We screened thirteen terms related to the patient's phenotypes in Human Phenotype Ontology (HPO) (Köhler et al., [2021](#page-6-12)): Absent eyebrow (HP:0002223), Absent eyelashes (HP:0000561), Aplasia/Hypoplasia of the eyebrow (HP:0100840), Poikiloderma (HP:0001029), Erythema (HP:0001029), Facial erythema (HP:0001041), Growth delay (HP:0001510), Short stature (HP:0004322), Small for gestational age (HP:0001518), Sparse eyebrow (HP:0045075), Sparse eyelashes (HP:0000653), Sparse hair (HP:0008070), and Sparse or absent eyelashes (HP:0200102). According

to the guidelines of the American College of Medical Genetics and Genomics (ACMG) (Richards et al., [2015](#page-7-13)), we interpreted all genes associated with these phenotypes, aiming to identify potentially pathogenic variants (shown in Figure [2a\)](#page-4-0). In this study, we employed classification criteria for determining pathogenicity, with each pathogenic criterion assigned a weight as follows: very strong (PVS1), strong (PS1-4), moderate (PM1-6), or supporting (PP1-5).

2.5 | **Sanger sequencing**

Sanger sequencing was conducted for validating the variants identified in WGS data. Primers for amplification were designed based on the *RECQL4* (GenBank NM_004260.3) sequence. The primer sequences were *RECQL4*_MIS_F: 5′-GTTCAGACGGCAATGGGTAT-3′; *RECQL4*_MIS_R: 5′-GCTGTGAAGAGGCTGGTACA-3′; *RECQL4*_INS_F: 5′-GTTAGGGGACAAGCAGCAGT-3′; and *RECQL4*_ INS_R: 5′-CAGTCATGCGGATCCTGTC-3′. The corresponding gDNA fragments from the patient and his parents were amplified, and the PCR products were sequenced using Sanger sequencing.

3 | **RESULTS**

3.1 | **Clinical characteristics**

Prenatal ultrasound showed that the fetus was consist-ently about a week smaller (Leung et al., [2008\)](#page-7-14) than expected and had decreased amniotic fluid in the later stages (shown in Table [1\)](#page-2-0). After birth, the patient continued to experience growth retardation and was small in height and weight. At 2 months of age, he developed red rashes on his face which spread to his entire body. He had sparse hair, no eyelashes, and no eyebrows (shown in Figure [1](#page-3-0)).

3.2 | **Molecular genetic analysis**

To determine the cause, we obtained all CNVs, SNVs, and Indels. The guidelines of ACMG were followed to identify pathogenic variants. Upon interpretation, none of the identified CNVs were classified as pathogenic or possibly pathogenic. However, two variants in *RECQL4* (GenBank NM 004260.3) associated with RTS were identified, including a frameshift variant c.1547dupC, p.Leu517AlafsTer23 (exon 9), and a nonsense variant c.2752G>T, p.Glu918Ter (exon 16). The two compound heterozygous mutations were confirmed by Sanger sequencing, and it was also demonstrated that the patient inherited the frameshift and the nonsense mutations from both parents (shown in Figure [2b,c\)](#page-4-0). Based on the ACMG guidelines, the two variants were categorized as pathogenic mutations. Due to the following evidence, the frameshift variant was classified as a pathogenic variation: (1) PVS1: null variant (frameshift) affecting gene *RECQL4*; (2) in ESP, 1000 Genomes Project, or gnomAD, the mutation is either absent from controls or has an extremely low frequency if recessive; (3) PM3: for autosomal recessive genes, a pathogenic variant detected in trans in the patient; and (4) PP3: the computational analysis concluded that the variant is pathogenic, as GERP predicted one pathogenic effect and no benign effects were detected. Due to the following evidence, the nonsense variant was classified as a pathogenic variation: (1) PVS1: null variant (nonsense) affecting gene *RECQL4*; (2) PM2: variant not found in gnomAD exomes and gnomAD genomes; (3) PM3: for autosomal recessive genes, a pathogenic variant detected in trans in the patient; (4) PP3: the computational assessment determined that the variant was pathogenic based on two pathogenic predictions from Genomic Evolutionary Rate Profiling (GERP) (Davydov et al., [2010\)](#page-6-13) and Functional Analysis through Hidden Markov Models—Multiple Kernel Learning (FATHMM-MKL) (Shihab et al., [2013\)](#page-7-15), with no benign predictions; and (5) PP5: ClinVar (Landrum et al., [2020](#page-6-14)) classifies the variant as pathogenic with one star (above

TABLE 1 Prenatal ultrasound.

Measurement gestational weeks BPD (cm) AC (cm) FL (cm) HC (cm) DVP (cm) AFI (cm) Fetal growth 23weeks+2days 5.04 (5.1–6.3) 17.86 (16.4–20.4) 3.78 (3.5–4.3) 20.40 (19.1–22.6) 3.0 (3–7) 8.9 (8–25) 22weeks+1day 27weeks+6days 6.60 (6.4–7.7) 22.30 (21.0–25.6) 5.10 (4.5–5.4) 24.80 (23.9–27.6) 3.9 (3–7) 11.3 (8–25) 26weeks+5days 31weeks+6days 7.70 (7.4–8.8) 26.50 (24.6–29.9) 5.90 (5.3–6.3) 28.10 (24.6–29.9) 5.4 (3–7) – 30weeks+4days 36weeks+3days 8.70 (8.3–9.6) 31.60 (28.3–34.3) 6.62 (6.1–7.1) 31.24 (30.0–34.0) 3.7 (3–7) 9.4 (8–25) – 39weeks+2days 8.86 (8.6–10.0) 30.88 (30.4–36.8) 7.19 (6.6–7.6) 31.46 (30.9–35.0) 1.6 (3–7) 4.6 (8–25) –

Note: Reference ranges are shown in parentheses (−2 SD/+ 2 SD) (Schwarz et al., [2014\)](#page-7-12).

Abbreviations: AC, abdominal circumference; AFI, amniotic fluid index; BPD, biparietal diameter; DVP, deepest vertical pocket; FL, femur length; HC, head circumference.

FIGURE 1 Clinical features of the patient: red rashes on the face, sparse hair, and absence of eyebrows.

a minimum of 1 star), but there is no evidence from func tional or in vivo studies to support PS3 (shown in Table [2\)](#page-3-1).

4 | **DISCUSSION/CONCLUSION**

In this study, we carried out WGS of a trio with a RTS proband manifesting red rashes on face, sparse hair, no eyelashes, and no eyebrows and identified compound het erozygous mutations in the *RECQL4* gene, which expands the mutation spectrum of *RECQL4*. We collected and ana lyzed follow-up data from the patient and conducted preg nancy examinations of the child's mother. We found that the fetal growth of the patient was consistently small for approximately 1week, enriching the phenotype spectrum of Chinese RTS patients.

The c.1547dupC (p.Leu517AlafsTer23) variant we discovered is a newly identified truncating mutation. The c.2752G >T (p.Glu918Ter) variant was previously reported as a nonsense mutation (Clinvar database: VCV000597188.3). Neither of these two mutations was found in the population, based on 1000 Genomes, ExAC, and East Asian population databases, or our local data base. The c.2752G >A (p.Glu918Lys) and c.1547C >T (p.Ala516Val) variants were also identified in the Clinvar database (Clinvar database: VCV002387422.1 and VCV002189648.1) at the same site as our newly identi fied mutation. However, neither of these two variants had significant clinical significance or relevant case reports, indicating the variants we found were extremely rare in the general population. The *RECQL4* gene comprises 21

TABLE 2 Two variants were identified in *RECQL4* (GenBank NM_004260.3) associated with RTS. DLC $......$ 0.77 and 40 \cdot D

FIGURE 2 (a) The filtering and analysis process of variants from 472 genes associated with 13 phenotypes in HPO. (b) Two compound heterozygous mutations were confirmed. The patient inherited the missense and the nonsense mutations from both parents. (c) Sanger sequencing results of the compound heterozygous variants of *RECQL4* .

 (a) Variants from 472 genes associated with HPO phenotypes are selected for analysis AF<5%(gnomAD,10 AF>5% (gnomAD,1000Ge-00Genomes) nomes) excluded Exonic variants (Inframe, frameshift, Intergenic variants, intronic varinonsense, missense, synonymous) and ants, upstream/downstream variants, splicing donor/acceptor site variants **UTR** variants Known pathogenic variants (ClinVar, HGMD) **Classification by ACMG guidelines (Pathogenic)** Analysis of parents and patient RECQL4 c.1547dupC(p.Leu517AlafsTer23) /--/c.2752G>T(p.Glu918Ter) (b) c.1547dupC (p.Leu517AlafsTer23) c.2752G>T (p.Glu918Ter) c.1547dupC(p.Leu517AlafsTer23) / c.2752G>T(p.Glu918Ter) (c) WT CCAGCGCTGCT WT C G G A G G A G G G T MT CCAGCCGCTGC Father c.1547dupC (p.Leu517AlafsTer23) WT CCAGCGCTGCT CGGAGGAGGGT **WT** WT C G G A G T A G G G T $\mathsf{M}\mathsf{T}$ Mother WT c.2752G>T (p.Glu918Ter) WT CGGAGGAGGGT WT CCAGCGCTGCT CCAGCCGCTGC MT CGGAGTAGGGT **MT** Patient

6 of 8 **WILEY** Molecular Genetics & Genomic Medicine **Access of al.** 2ENG ET AL.

exons (Ohlenschläger et al., [2012;](#page-7-16) Wang et al., [2003\)](#page-7-2). The c.1547dupC (p.Leu517AlafsTer23) mutation occurred in the helicase domain (exons 9-13) (Mann et al., [2005\)](#page-7-17), while the other identified mutation, c.2752G>T (p.Glu-918Ter), occurred downstream of the helicase domain. The c.2752G>T (p.Glu918Ter) mutation is a nonsense mutation that results in the substitution of an amino acid with a stop codon, leading to the termination of protein translation. The c.1547dupC (p.Leu517AlafsTer23) mutation is an insertion mutation that leads to reading frameshift and subsequent termination of protein translation. These mutations often lead to the destruction of the stability of mature mRNA through nonsense-mediated decay (Larizza et al., [2010](#page-7-1)). We predict that the new mutation, c.1547dupC, would destroy the helicase domain, resulting in the deletion, truncation, or damage of the helicase activity of the RECQL4 protein.

The 3-month-old patient had red rashes on his face, sparse hair, no eyelashes, and no eyebrows, which is consistent with the main clinical diagnostic hallmark of RTS (Larizza et al., [2010;](#page-7-1) Wang et al., [2001\)](#page-7-18). RTS patients are proportionately small in weight and height (Gui et al., [2018](#page-6-15); Yadav et al., [2019](#page-7-19); Zhang et al., [2021\)](#page-7-20). Low birth weight, slow weight gain, and linear growth deficiency are present in at least two-thirds of RTS patients (Wang et al., [2001](#page-7-18)). The patient in this study not only experienced growth retardation and small in height and weight after birth but also showed consistently about a week smaller as early as 23 gestational weeks estimated by prenatal ultrasound tests. RTS-related bone abnormalities have been recapitulated in mouse models. *Recql4* knockout mice died between embryonic days 3.5–6.5, showing that the DNA helicase functions fundamentally in embryonic development (Ichikawa et al., [2002](#page-6-16)). The homozygous *Recql4* exon 13-deleted mice exhibited severe growth retardation as early as embryonic day 14.5, showing short stature and low body weight (Hoki et al., [2003](#page-6-17)). *Recql4* conditional knockout mice targeting the skeletal lineage had limb defects, showing shorter forelimbs and hindlimbs (Lu et al., [2015\)](#page-7-21). An increased p53 response was seen in affected tissues, indicating Recql4 is critical for skeletal development by modulating p53 activity in vivo. Ng et al. [\(2015](#page-7-22)) also found that *Recql4* bone cells specifically removed mice also had shortened bones. Castillo-Tandazo et al. ([2021\)](#page-6-18) investigated mouse models with combination of a *Recql4* truncating mutation and a conditional null allele and found that different mutations led to distinct phenotypes. *Osx-Cre Recql4fl/R347X* mice had lower body weight and shorter tibial length compared with *Osx-Cre Recql4fl/⁺* mice, while *Osx-Cre Recql4fl/G522Efs* mice were not different (Yadav et al., [2019\)](#page-7-19). Collectively, Recql4 functions in skeletogenesis as early as embryonic development, and different mutations have different effects. We

can infer that the compound heterozygous mutations in *RECQL4* may be involved in the occurrence of the slow fetal growth of the proband. Knockin mouse models could help to elucidate the molecular pathogenesis.

This patient exhibited slow fetal growth for approximately 1week during the fetal stage, but he did not meet the diagnostic criteria for fetal growth restriction (FGR), manifesting as fetal ultrasound estimated weight or abdominal circumference below the 10th percentile for the corresponding gestational age (Fetal Medicine Subgroup, Chinese Society of Perinatal Medicine, Chinese Medical Association; Maternal-Fetal Medicine Committee, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, et al., [2022](#page-6-19)). His phenotype could be overlooked by clinicians. Therefore, this case also makes some suggestions for clinicians that pregnant women whose fetal growth and development consistently exhibit being about 1week behind and show no other significant abnormalities during pregnancy might consider whether prenatal diagnosis should be advised in addition to the necessary nutritional intervention. The use of highthroughput genome sequencing to identify pathogenic variants is a valuable tool for early disease diagnosis and has significant clinical implications for genetic counseling and fertility guidance. Additionally, carrier testing for atrisk relatives and preimplantation genetic diagnosis can assist the patient's parents in making informed decisions regarding their future fertility.

AUTHOR CONTRIBUTIONS

Clinical information collection: Juan Zeng and Sujun Zhu; sample collection and processing: Zhongzhen Liu, Jinghua Sun, Juan Zeng, and Sujun Zhu; data analysis: Qing Zhou, Wen-Jing Wang, Jinghua Sun, and Jiayi Li; writing—original draft: Jiayi Li, Rui Liang, Yuwei Liu, and Lin Wang; and writing—review and editing: Juan Zeng, Wen-Jing Wang, and Sujun Zhu. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

We would like to express our gratitude to the BGI research group and the doctors at Shenzhen Maternal and Child Health Hospital for their valuable contributions and insightful discussions. We are also deeply appreciative of the patient and his parents for their support in participating in this study. Furthermore, we extend our thanks to China National GeneBank (CNGB) for their support throughout the study.

FUNDING INFORMATION

This work was supported by the Science Technology and Innovation Commission of Shenzhen Municipality under Grant No. JCYJ20170412152854656.

CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest to declare.

DATA AVAILABILITY STATEMENT

This study's supporting data can be obtained by contacting the corresponding author. Please note that due to privacy and ethical restrictions, the data are not publicly available.

ETHICS STATEMENT

This study was conducted according to the criteria of the Declaration of Helsinki and was approved and guided by the Shenzhen Maternity and Child Healthcare Hospital [project: SFYLS (2019) NO137]. Written informed consent was obtained from the patient's parents for the publication of this paper.

ORCID

Wen-Jing Wang <https://orcid.org/0000-0002-4527-1168>

REFERENCES

- Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. *Nature Methods*, *7*(4), 248–249.
- Ajeawung, N. F., Nguyen, T. T. M., Lu, L., Kucharski, T. J., Rousseau, J., Molidperee, S., Atienza, J., Gamache, I., Jin, W., Plon, S. E., Lee, B. H., Teodoro, J. G., Wang, L. L., & Campeau, P. M. (2019). Mutations in ANAPC1, encoding a scaffold subunit of the anaphase-promoting complex, cause Rothmund-Thomson syndrome type 1. *American Journal of Human Genetics*, *105*(3), 625–630.
- Aymé, S. Schmidtke [Internet] The portal for rare diseases and orphan drugs. 2023. [cited 2023 Jan 12]. [https://www.orpha.net/](https://www.orpha.net/consor/cgi-bin/index.php) [consor/cgi-bin/index.php.](https://www.orpha.net/consor/cgi-bin/index.php)
- Castillo-Tandazo, W., Frazier, A. E., Sims, N. A., Smeets, M. F., & Walkley, C. R. (2021). Rothmund-Thomson syndrome-like RECQL4 truncating mutations cause a haploinsufficient lowbone-mass phenotype in mice. *Molecular and Cell Biology*, *41*(3), e0059020.
- Davydov, E. V., Goode, D. L., Sirota, M., Cooper, G. M., Sidow, A., & Batzoglou, S. (2010). Identifying a high fraction of the human genome to be under selective constraint using GERP*++*. *PLoS Computational Biology*, *6*(12), e1001025.
- Exome Variant Server. NHLBI GO Exome Sequencing Project (ESP). 2022. [cited 2022 Oct 31]. <http://evs.gs.washington.edu/EVS/>
- Fairley, S., Lowy-Gallego, E., Perry, E., & Flicek, P. (2019). The international genome sample resource (IGSR) collection of open human genomic variation resources. *Nucleic Acids Research*, *48*(D1), D941–D947.
- Fetal Medicine Subgroup, Chinese Society of Perinatal Medicine, Chinese Medical Association; Maternal-Fetal Medicine Committee, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, Sun, L., Hu, Y., & Qi, H. (2022). A summary of Chinese expert consensus on fetal growth restriction (an update on the 2019 version). *Maternal-Fetal Medicine*, *4*(3), 162–168.
- Ghosh, A. K., Rossi, M. L., Singh, D. K., Dunn, C., Ramamoorthy, M., Croteau, D. L., Liu, Y., & Bohr, V. A. (2012). *RECQL4*, the protein mutated in Rothmund-Thomson syndrome, functions in telomere maintenance. *The Journal of Biological Chemistry*, *287*(1), 196–209.
- Gui, B., Song, Y., Hu, X., Li, H., Qin, Z., Su, J., Li, C., Fan, X., Li, M., Luo, J., Feng, Y., Song, L., Chen, S., Gong, C., & Shen, Y. (2018). Novel pathogenic RECQL4 variants in Chinese patients with Rothmund-Thomson syndrome. *Gene*, *654*, 110–115.
- Hoki, Y., Araki, R., Fujimori, A., Ohhata, T., Koseki, H., Fukumura, R., Nakamura, M., Takahashi, H., Noda, Y., Kito, S., & Abe, M. (2003). Growth retardation and skin abnormalities of the Recql4 -deficient mouse. *Human Molecular Genetics*, *12*(18), 2293–2299.
- Ichikawa, K., Noda, T., & Furuichi, Y. (2002). Preparation of the gene targeted knockout mice for human premature aging diseases, Werner syndrome, and Rothmund-Thomson syndrome caused by the mutation of DNA helicases. *Nippon Yakurigaku Zasshi*, *119*, 219–226.
- Kang, J., Zhou, Q., Chen, N., Liu, Z., Zhang, Y., Sun, J., Ma, C., Chen, F., Ma, Y., Wang, L., Zhu, L., & Wang, W. (2022). Clinical and genetic characteristics of a cohort with distal vaginal atresia. *International Journal of Molecular Sciences*, *23*(21), 12853.
- Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., Gauthier, L. D., Brand, H., Solomonson, M., Watts, N. A., Rhodes, D., Singer-Berk, M., England, E. M., Seaby, E. G., Kosmicki, J. A., … MacArthur, D. G. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*, *581*(7809), 434–443.
- Kim, H., Choi, H., Im, J. S., Park, S. Y., Shin, G., Yoo, J. H., Kim, G., & Lee, J. K. (2021). Stable maintenance of the Mre11-Rad50-Nbs1 complex is sufficient to restore the DNA double-strand break response in cells lacking *RECQL4* helicase activity. *The Journal of Biological Chemistry*, *297*(4), 101148.
- Kitao, S., Lindor, N. M., Shiratori, M., Furuichi, Y., & Shimamoto, A. (1999). Rothmund-Thomson syndrome responsible gene, *RECQL4*: Genomic structure and products. *Genomics*, *61*(3), 268–276.
- Kitao, S., Ohsugi, I., Ichikawa, K., Goto, M., Furuichi, Y., & Shimamoto, A. (1998). Cloning of two new human helicase genes of the RecQ family: Biological significance of multiple species in higher eukaryotes. *Genomics*, *54*(3), 443–452.
- Köhler, S., Gargano, M., Matentzoglu, N., Carmody, L. C., Lewis-Smith, D., Vasilevsky, N. A., Danis, D., Balagura, G., Baynam, G., Brower, A. M., Callahan, T. J., Chute, C. G., Est, J. L., Galer, P. D., Ganesan, S., Griese, M., Haimel, M., Pazmandi, J., Hanauer, M., … Robinson, P. N. (2021). The human phenotype ontology in 2021. *Nucleic Acids Research*, *49*(D1), D1207–D1217.
- Kumar, P., Henikoff, S., & Ng, P. C. (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nature Protocols*, *4*(7), 1073–1081.
- Landrum, M. J., Chitipiralla, S., Brown, G. R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur, K., Liu, C., Lyoshin, V., Maddipatla, Z., Maiti, R., Mitchell, J., O'Leary, N., Riley, G. R., Shi, W., Zhou, G., Schneider, V., … Kattman, B. L. (2020). ClinVar: Improvements to accessing data. *Nucleic Acids Research*, *48*(D1), D835–D844.
- Larizza, L., Roversi, G., & Verloes, A. (2013). Clinical utility gene card for: Rothmund-Thomson syndrome. *European Journal of Human Genetics*, *21*(7), 792.
- Larizza, L., Roversi, G., & Volpi, L. (2010). Rothmund-Thomson syndrome. *Orphanet Journal of Rare Diseases*, *5*, 2.
- Leung, T. N., Pang, M. W., Daljit, S. S., Leung, T. Y., Poon, C. F., Wong, S. M., & Lau, T. K. (2008). Fetal biometry in ethnic Chinese: Biparietal diameter, head circumference, abdominal circumference and femur length. *Ultrasound in Obstetrics & Gynecology*, *31*(3), 321–327.
- Li, X., Chen, S., Xie, W., Vogel, I., Choy, K. W., Chen, F., Christensen, R., Zhang, C., Ge, H., Jiang, H., Yu, C., Huang, F., Wang, W., Jiang, H., & Zhang, X. (2014). PSCC: Sensitive and reliable population-scale copy number variation detection method based on low coverage sequencing. *PLoS One*, *9*(1), e85096.
- Liu, Y. (2010). Rothmund-Thomson syndrome helicase, RECQ4: On the crossroad between DNA replication and repair. *DNA Repair (Amst)*, *9*(3), 325–330.
- Lu, H., & Davis, A. J. (2021). Human RecQ helicases in DNA double-Strand break repair. *Frontiers in Cell and Development Biology*, *9*, 640755.
- Lu, L., Harutyunyan, K., Jin, W., Wu, J., Yang, T., Chen, Y., Joeng, K. S., Bae, Y., Tao, J., Dawson, B. C., Jiang, M. M., Lee, B., & Wang, L. L. (2015). RECQL4 regulates p53 function in vivo during skeletogenesis. *Journal of Bone and Mineral Research*, *30*(6), 1077–1089.
- Mann, M. B., Hodges, C. A., Barnes, E., Vogel, H., Hassold, T. J., & Luo, G. (2005). Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. *Human Molecular Genetics*, *14*(6), 813–825.
- Ng, A. J. M., Walia, M. K., Smeets, M. F., Mutsaers, A. J., Sims, N. A., Purton, L. E., Walsh, N. C., Martin, T. J., & Walkley, C. R. (2015). The DNA helicase Recql4 is required for normal osteoblast expansion and osteosarcoma formation. *PLoS Genetics*, *11*(4), e1005160.
- Ohlenschläger, O., Kuhnert, A., Schneider, A., Haumann, S., Bellstedt, P., Keller, H., Saluz, H. P., Hortschansky, P., Hänel, F., Grosse, F., Görlach, M., & Pospiech, H. (2012). The N-terminus of the human *RECQL4* helicase is a homeodomain-like DNA interaction motif. *Nucleic Acids Research*, *40*(17), 8309–8324.
- Ren, S., Bertels, K., & Al-Ars, Z. (2018). Efficient acceleration of the pair-HMMs forward algorithm for GATK HaplotypeCaller on graphics processing units. *Evolutionary Bioinformatics Online*, *14*, 1176934318760543.
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., Rehm, H. L., & ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*, *17*(5), 405–424.
- Sangrithi, M. N., Bernal, J. A., Madine, M., Philpott, A., Lee, J., Dunphy, W. G., & Venkitaraman, A. R. (2005). Initiation of DNA replication requires the *RECQL4* protein mutated in Rothmund-Thomson syndrome. *Cell*, *121*(6), 887–898.
- Schwarz, J. M., Cooper, D. N., Schuelke, M., & Seelow, D. (2014). MutationTaster2: Mutation prediction for the deep-sequencing age. *Nature Methods*, *11*(4), 361–362.
- Sherry, S. T., Ward, M. H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M., & Sirotkin, K. (2001). dbSNP: The NCBI database of genetic variation. *Nucleic Acids Research*, *29*(1), 308–311.
- Shihab, H. A., Gough, J., Cooper, D. N., Stenson, P. D., Barker, G. L., Edwards, K. J., Day, I. N. M., & Gaunt, T. R. (2013). Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Human Mutation*, *34*(1), 57–65.
- Siitonen, H. A., Sotkasiira, J., Biervliet, M., Benmansour, A., Capri, Y., Cormier-Daire, V., Crandall, B., Hannula-Jouppi, K., Hennekam, R., Herzog, D., Keymolen, K., Lipsanen-Nyman, M., Miny, P., Plon, S. E., Riedl, S., Sarkar, A., Vargas, F. R., Verloes, A., Wang, L. L., … Kestilä, M. (2009). The mutation spectrum in *RECQL4* diseases. *European Journal of Human Genetics*, *17*(2), 151–158.
- Wang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., Lev, D., Rogers, M., Zackai, E. H., & Plon, S. E. (2003). Association between osteosarcoma and deleterious mutations in the *RECQL4* gene in Rothmund-Thomson syndrome. *Journal of the National Cancer Institute*, *95*(9), 669–674.
- Wang, L. L., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Lev, D., Rogers, M., & Plon, S. E. (2001). Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. *American Journal of Medical Genetics*, *102*(1), 11–17.
- Wang, L. L., Worley, K., Gannavarapu, A., Chintagumpala, M. M., Levy, M. L., & Plon, S. E. (2002). Intron-size constraint as a mutational mechanism in Rothmund-Thomson syndrome. *American Journal of Human Genetics*, *71*(1), 165–167.
- Xu, X., & Liu, Y. (2009). Dual DNA unwinding activities of the Rothmund-Thomson syndrome protein, RECQ4. *The EMBO Journal*, *28*(5), 568–577.
- Yadav, S., Thakur, S., Kohlhase, J., Bhari, N., Kabra, M., & Gupta, N. (2019). Report of two novel mutations in Indian patients with Rothmund-Thomson syndrome. *Journal of Pediatric Genetics*, *8*(3), 163–167.
- Zhang, Y., Qin, W., Wang, H., Lin, Z., Tang, Z., & Xu, Z. (2021). Novel pathogenic variants in the RECQL4 gene causing Rothmund-Thomson syndrome in three Chinese patients. *The Journal of Dermatology*, *48*(10), 1511–1517.

How to cite this article: Zeng, J., Li, J., Liu, Y., Liang, R., Wang, L., Zhou, Q., Sun, J., Liu, Z., Wang, W.-J., & Zhu, S. (2024). A Chinese patient with Rothmund–Thomson syndrome. *Molecular Genetics & Genomic Medicine*, *12*, e2347. [https://doi.](https://doi.org/10.1002/mgg3.2347) [org/10.1002/mgg3.2347](https://doi.org/10.1002/mgg3.2347)